Ani Pharmaceuticals's top three insider shareholders as of March 23, 2026 are Venture Partners Ii Lp Meridian (TenPercentOwner, 1.82Mn shares), Muthusamy Shanmugam (Head Of Rd, Coo Novitium Ops, 431.92K shares), Nikhil Lalwani (President Ceo, 404.89K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Venture Partners Ii Lp Meridian | 1,819,259 | 0 | 16 Aug, 2023 | |
| Muthusamy Shanmugam | Head Of Rd, Coo Novitium Ops | 0 | 431,920 | 22 Aug, 2025 |
| Nikhil Lalwani | President Ceo | 404,889 | 0 | 10 Mar, 2026 |
| Stephen P. Carey | Svp Cfo | 180,393 | 0 | 10 Mar, 2026 |
| Chad Gassert | Svp Corp. Dev. Strategy | 0 | 158,490 | 14 Nov, 2025 |
| James G. Marken | Svp Ops Prod Dev | 117,829 | 0 | 11 Jun, 2024 |
| Muthusamy Shanmugam | Head Of Rd, Coo Novitium Ops | 101,056 | 0 | 02 Mar, 2026 |
| Christopher Mutz | Head Of Rare Disease | 91,309 | 0 | 13 Mar, 2026 |
| Ori Gutwerg | Svp, Generics | 81,468 | 0 | 10 Mar, 2026 |
| Meredith Cook | Sr. Vp, General Counsel Sec. | 79,390 | 0 | 13 Mar, 2026 |
| Chad Gassert | Svp Corp. Dev. Strategy | 74,916 | 0 | 02 Mar, 2026 |
| Patrick D Walsh | 52,405 | 0 | 03 Mar, 2026 | |
| Krista Davis | Svp, Chief Hr Officer | 51,946 | 0 | 10 Mar, 2026 |
| Robert E. Jr Brown | 49,021 | 0 | 29 Apr, 2022 | |
| Thomas Andrew Rowland | Svp, Head Established Brands | 38,730 | 0 | 13 Mar, 2026 |
| David Nash | 38,561 | 0 | 24 May, 2023 | |
| Thomas Haughey | 36,521 | 0 | 14 Aug, 2025 | |
| Renee P Tannenbaum | 25,157 | 0 | 09 Dec, 2025 | |
| Jeanne Thoma | 23,405 | 0 | 20 Aug, 2025 | |
| Antonio R Pera | 22,660 | 0 | 04 Sep, 2025 | |
| Matthew J Leonard | 6,864 | 0 | 26 Aug, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 13 Mar, 2026 | Christopher Mutz | Common Stock | D | 3,162 | $71.64 | 91,309 | D | S |
| 13 Mar, 2026 | Meredith Cook | Common Stock | D | 500 | $72.62 | 79,390 | D | S |
| 11 Mar, 2026 | Thomas Andrew Rowland | Common Stock | D | 4,772 | $74.91 | 38,730 | D | S |
| 06 Mar, 2026 | Krista Davis | Common Stock | D | 1,485 | $75.00 | 57,033 | D | S |
| 06 Mar, 2026 | Christopher Mutz | Common Stock | D | 2,121 | $74.22 | 101,387 | D | S |
| 07 Mar, 2026 | Ori Gutwerg | Common Stock | D | 3,314 | $74.04 | 81,468 | D | F |
| 07 Mar, 2026 | Stephen P. Carey | Common Stock | D | 5,150 | $74.04 | 180,393 | D | F |
| 07 Mar, 2026 | Nikhil Lalwani | Common Stock | D | 17,060 | $74.04 | 404,889 | D | F |
| 09 Mar, 2026 | Krista Davis | Common Stock | D | 5,087 | $74.13 | 51,946 | D | S |
| 07 Mar, 2026 | Christopher Mutz | Common Stock | D | 3,314 | $74.04 | 98,073 | D | F |
| 09 Mar, 2026 | Christopher Mutz | Common Stock | D | 3,602 | $74.18 | 94,471 | D | S |
| 05 Mar, 2026 | Stephen P. Carey | Common Stock | A | 3,312 | $49.51 | 192,855 | D | M |
| 05 Mar, 2026 | Stephen P. Carey | Common Stock | D | 3,312 | $75.42 | 189,543 | D | S |
| 05 Mar, 2026 | Stephen P. Carey | Common Stock | D | 4,000 | $75.56 | 185,543 | D | S |
| 05 Mar, 2026 | Stephen P. Carey | Stock Option (right to buy) | D | 3,312 | $49.51 | 9,938 | D | M |
| 03 Mar, 2026 | Ori Gutwerg | Common Stock | D | 2,060 | $76.50 | 84,782 | D | S |
| 02 Mar, 2026 | Christopher Mutz | Common Stock | D | 417 | $74.00 | 103,508 | D | S |
| 03 Mar, 2026 | Patrick D Walsh | Common Stock | D | 6,000 | $74.23 | 52,405 | D | S |
| 26 Feb, 2026 | Ori Gutwerg | Common Stock | A | 12,969 | $77.15 | 89,063 | D | A |
| 26 Feb, 2026 | Chad Gassert | Common Stock | A | 11,116 | $77.15 | 77,137 | D | A |